Physician profile
William J Levy
NPI 1801826342
$4,405.18
in general payments reported to CMS, 2019-2025
39 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $288 · 2021: $504 · 2022: $295 · 2023: $522 · 2024: $645 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $666.95 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $654.93 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $276.47 | 2019-2025 | |
| Abbott Laboratories | $256.88 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.30 | 2019-2025 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $233.25 | 2019-2025 | |
| Dexcom, INC. | $201.50 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi US Services INC. | $200.00 | 2021 | |
| Corcept Therapeutics | $195.05 | 2020-2025 | Korlym |
| Medtronic, INC. | $126.03 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Tandem Diabetes Care, INC. | $119.42 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $92.46 | 2019-2022 | |
| Madrigal Pharmaceuticals | $91.65 | 2025 | Rezdiffra |
| Cequr Corporation | $89.77 | 2023-2025 | Cequr Simplicity |
| Shire North American Group INC | $85.39 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $76.00 | 2019-2025 | Omnipod |
| Genzyme Corporation | $72.00 | 2020 | |
| Amgen INC. | $67.31 | 2023-2025 | Evenity, Prolia |
| Horizon Therapeutics Plc | $65.00 | 2019 | |
| Beta Bionics, INC. | $56.18 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $54.51 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $47.71 | 2022-2024 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $45.65 | 2025 | Twiist |
| Lifescan, INC. | $44.44 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $39.36 | 2024-2025 | Strensiq |
| Radius Health, INC. | $38.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.18 | 2019 | |
| Ibsa Pharma INC. | $29.32 | 2021-2023 | Tirosint, Licart |
| Amarin Pharma, INC. | $28.06 | 2020 | |
| Mannkind Corporation | $22.93 | 2020-2021 | |
| Glaxosmithkline, LLC. | $22.19 | 2025 | Shingrix |
| Siemens Medical Solutions USA, INC. | $19.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $19.17 | 2024 | Unithroid |
| Medtronic Minimed, INC. | $19.06 | 2019 | |
| Recordati_rare_diseases_inc. | $17.82 | 2025 | Isturisa |
| Pfizer INC. | $17.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.65 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.57 | 2020 | |
| Intuity Medical INC | $14.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.